Category: Deals Roundup
Medical device maker Insulet teams up with pharmaceutical giant Eli Lilly in development of an insulin pump designed for patients with a highly insulin resistant form of diabetes.
Third Rock Ventures partner Neil Exter tells MassDevice.com about the firm's latest $516 million fund, how it plans to launch 15-16 new companies in the life sciences space and how its unique investment and development strategy paves the way for success.
Third Rock Ventures, one of the premiere healthcare venture capital firms, is loaded for bear again.
The Boston-based VC group recently closed its 3rd fund, a $516 million tranche that will go towards launching some 15 to16 new life science companies in the coming months. In the past 6 years Third Rock Ventures has raised more than $1.3 billion and launched some 31 companies across the life sciences spectrum.
There were fewer mergers and acquisitions in 2012 than in 2011 but the deals were more valuable, and analysts foresee more activity ahead in 2013.
The medical device sector posted some strong merger & acquisition figures in 2012, and the year ahead is looking bright as well, according to a report from analysts at PricewaterhouseCoopers.
Angiotech Pharmaceuticals sells its interventional products business back to previous overseer Argon Medical for $362.5 million, planning to use part of the funds to repay repay all of its outstanding debts.
Angiotech Pharmaceuticals plans to retire all of its outstanding debt obligations with part of the $362.5 million it stands to gain through the sale of its interventional products business back to Argon Medical Devices.
In a merger of Massachusetts-based aesthetic laser companies, Cynosure purchases Palomar Medical for $234 million in cash and stock.
Aesthetic laser maker Cynosure (NSDQ:CYNO) snapped up another competitor, acquiring Palomar Medical (NSDQ:PMTI) for $294 million in cash and stock.
Stryker buys spinal implact technology from VertiFlex for an undisclosed amount.
Stryker's (NYSE:SYK) spine division acquired some non-core assets from medical device company VertiFlex for an undisclosed amount.
San Clemente, Calif.-based VertiFlex said the technology is "not core to the ongoing strategic operations of the company" and that it plans to us the cash for its line of lumbar spinal stenosis products.